Enzymes are increasingly being recognized as potential targets in drug discovery and GVK BIO offers high quality, customized assay development solutions with various readouts and formats to help you reach your goals quickly and cost effectively. With a flexibility to adapt assays developed at the client’s site, we take up the task of screening at our facility. Our scientific team with sound technical and analytical skills has developed more than 200 assays against targets that include GPCRs, Ion channels, transporters, and several kinases with novel methodology. The dedicated facility for radioactive assay readouts enables us to handle assay volumes that range from low to high throughput screening of drug candidates using radiolabeled C, P and H reagents.
We routinely use biochemical assay development technologies such as, Luminescence, Fluorescence, Fluorescence Polarization, IMAP, Time Resolved FRET (HTRF), Alpha Screen, SPA, etc. and Cellular Assay Technologies, typically including reporter gene assay, DELFIA, ELISA, CLIA, Alpha Lisa, and more.
Our receptor biology team has proven capabilities in executing receptor binding and functional assays. With the collaborative efforts of our molecular biology team, we generate stable cells expressing target receptors. Our state-of-the-art cell culture lab enables us to culture at least 5 billion cells every week. Membranes are prepared from bulk cells, characterized, validated, and used in the binding assay for screening of NCEs. Alternately, we incorporate provisions for freeze storage of cells for future revival and culture. We employ filtration or SPA technologies for the binding assays.
Radioligand binding assays are developed for several therapeutic targets. Our targets include: